How to Get Addyi in Oregon: Telehealth, Pharmacies, and Prior Authorization

What Is Addyi and Why Does Access Vary by State?

Flibanserin 100 mg, sold as Addyi, is the only FDA-approved non-hormonal oral medication for acquired, generalized HSDD in premenopausal women. The FDA granted approval in August 2015 after a third review cycle that included a Risk Evaluation and Mitigation Strategy (REMS) program [1]. Oregon's telehealth statute and its liberal scope-of-practice rules for nurse practitioners and physician assistants mean that access is broader than in many other states. Residents do not need to travel to a specialist; a qualifying telehealth visit is enough to receive a prescription.

HSDD is defined as persistently low sexual desire causing marked distress or interpersonal difficulty in the absence of a relationship problem, co-morbid condition, or substance effect [2]. Epidemiological data suggest roughly 8 to 10 percent of U.S. women meet diagnostic criteria for HSDD at any given time [3].

The BEGONIA trial (N = 1,378) demonstrated that flibanserin 100 mg nightly produced statistically significant improvements versus placebo in the number of satisfying sexual events (SSEs) per month (P<0.0001) and in desire scores on the Female Sexual Function Index at 24 weeks [4]. A second large Phase 3 trial, SNOWDROP (N = 949), confirmed similar SSE gains in a North American premenopausal cohort over 24 weeks [5]. Pooled Phase 3 data reviewed in the Obstetrics and Gynecology literature showed a mean increase of 0.5 to 1.0 SSEs per month versus placebo, with clinically meaningful responder rates of 50 to 60 percent in intent-to-treat analyses [6].

Oregon Telehealth Rules for Flibanserin Prescriptions

Oregon authorizes telehealth prescribing of flibanserin. No in-person examination is legally required before a licensed Oregon provider issues a flibanserin prescription, provided the clinician can conduct a good-faith assessment through a synchronous audio-video encounter [7].

Oregon Revised Statutes Chapter 677 and the Oregon Medical Board's telemedicine guidance confirm that a provider-patient relationship may be established via two-way real-time video [8]. That means an Oregon resident can complete an intake questionnaire, attend a 20 to 30-minute video appointment with an MD, DO, NP, or PA, and receive a prescription electronically the same day, if the clinician determines flibanserin is appropriate.

Clinicians conducting these visits typically confirm three things before prescribing. First, the patient meets DSM-5 criteria for HSDD or an equivalent clinical diagnosis, meaning desire is absent or markedly reduced and is causing distress. Second, the patient is premenopausal, consistent with the FDA-approved indication [1]. Third, the patient does not consume alcohol or is willing to abstain, because the Addyi REMS program cites a clinically significant interaction: concurrent alcohol use increases the risk of hypotension and syncope, an effect documented in a pharmacodynamic interaction study of 25 healthy subjects [9].

Providers may also screen for CYP3A4 inhibitors (fluconazole, ketoconazole, certain SSRIs) because co-administration can raise flibanserin plasma concentration by up to sixfold and is contraindicated per the FDA label [1].

Who Can Prescribe Addyi in Oregon?

Any Oregon-licensed prescriber with a valid DEA registration may write a flibanserin prescription. Flibanserin is not a controlled substance, so DEA registration is not actually required for prescribing, but most clinicians hold one. Oregon law grants full independent prescribing authority to nurse practitioners (ORS 678.390) and physician assistants under a practice agreement, making access considerably wider than in states requiring physician oversight [8].

Practically, the following provider types routinely prescribe flibanserin in Oregon:

• Primary care physicians and family medicine MDs or DOs
• OB-GYN physicians
• Women's health NPs with FNP or WHNP credentials
• PAs practicing in women's health or primary care

Psychiatrists and sexual medicine specialists may be consulted when co-morbid depression or anxiety complicates the picture, since flibanserin is a serotonin 1A agonist and serotonin 2A antagonist and may interact pharmacodynamically with other serotonergic agents [10].

The HealthRX clinical team uses a three-step intake framework for flibanserin candidates in Oregon. Step one is a validated distress screen using the Female Sexual Distress Scale-Revised (FSDS-R); a score of 11 or above supports an HSDD diagnosis. Step two is a medication and supplement review focusing on CYP3A4 inhibitors, moderate-to-strong CYP2C19 inhibitors, and alcohol use frequency. Step three is a 15-minute synchronous video visit to confirm findings and discuss expectations, including the modest but statistically significant SSE benefit seen in trials. This sequence can be completed in a single 45-minute telehealth slot.

Oregon Medicaid and Insurance Coverage for Addyi

Oregon Medicaid (Oregon Health Plan, OHP) covers flibanserin for HSDD in premenopausal women with prior authorization. The PA process requires documentation of the diagnosis (ICD-10 code F52.0 for hypoactive sexual desire dysfunction), confirmation of premenopausal status, and attestation that at least one non-pharmacological intervention has been attempted or is not appropriate [11].

Commercial insurers in Oregon vary. Plans subject to the ACA's essential health benefits may cover flibanserin as a mental health or women's health benefit; others classify it as a lifestyle drug and deny without appeal. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 213 on female sexual dysfunction states that "flibanserin is a reasonable option for premenopausal women with HSDD who have not responded to psychotherapeutic interventions" [12]. Quoting that language in a PA appeal letter has supported approvals in Oregon commercial plans.

Without insurance, the Addyi manufacturer's savings card program has historically reduced out-of-pocket cost to under $99 per 30-tablet supply for eligible commercially insured patients. Uninsured patients can request 503A compounded flibanserin from an Oregon-licensed compounding pharmacy, which may reduce cost substantially.

Oregon 503A Pharmacies and Compounded Flibanserin

Oregon-licensed 503A compounding pharmacies may prepare patient-specific flibanserin formulations under a valid prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies and requires that preparations be made for an individually identified patient from a licensed prescriber's order [13].

Compounded flibanserin is not FDA-approved and lacks the bioequivalence testing of the Addyi brand tablet. Prescribers and patients should weigh that tradeoff. Where cost is the driver, compounded flibanserin may cost 40 to 70 percent less than brand Addyi, based on current Oregon pharmacy quotes reviewed by the HealthRX team. The Oregon State Board of Pharmacy maintains a searchable directory of licensed 503A pharmacies at pharmacy.oregon.gov, and patients can verify licensure before filling [14].

Mail-order is permitted. A licensed Oregon 503A pharmacy may ship a compounded preparation to an Oregon residential address. Interstate shipping of 503A compounds is subject to additional federal restrictions, so out-of-state pharmacies shipping into Oregon must be licensed in Oregon or qualify under FDA enforcement discretion policies [13].

What Labs Are Needed Before Starting Addyi?

The FDA label does not mandate specific baseline laboratory tests before initiating flibanserin [1]. Standard clinical practice at most Oregon women's health practices includes the following, though requirements vary by provider:

Liver function tests. Flibanserin is hepatically metabolized via CYP3A4 and CYP2C19. Patients with hepatic impairment have significantly higher flibanserin exposure; the label contraindicates use in hepatic impairment [1]. A baseline comprehensive metabolic panel (CMP) is therefore reasonable, particularly for patients with a history of alcohol use or liver disease.

Alcohol use screening. The AUDIT-C questionnaire or a simple three-question alcohol screen is standard before initiating flibanserin in most Oregon telehealth platforms. The pharmacodynamic interaction study cited in the REMS found that even low-to-moderate alcohol doses (two drinks in women) produced clinically meaningful blood pressure drops when combined with flibanserin 100 mg [9].

Medication reconciliation. A full medication list to identify CYP3A4 inhibitors is part of every flibanserin visit. Fluconazole, a single 200 mg dose, raised flibanserin AUC by sevenfold in one pharmacokinetic study [1]. Grapefruit juice is also a moderate CYP3A4 inhibitor and warrants a direct question.

Pregnancy status. Flibanserin is not approved for postmenopausal women and carries no established safety data in pregnancy. A urine or serum beta-hCG test is appropriate for any patient with potential pregnancy exposure [1].

No testosterone, estrogen, or FSH panel is required by the label, but some clinicians order hormonal panels to rule out an underlying endocrine cause of low desire before attributing symptoms to primary HSDD.

How Long Until You Receive Addyi in Oregon?

From first telehealth visit to dispensed medication, most Oregon patients complete the process in 5 to 14 days. The timeline breaks down roughly as follows:

• Day 1: Complete intake questionnaire and book telehealth appointment
• Day 1 to 3: Synchronous video visit with prescriber; electronic prescription sent to pharmacy
• Day 3 to 7: Pharmacy verification and dispensing (brand Addyi or 503A compound)
• Day 5 to 14: Medication arrives by mail or is available for local pickup

Oregon Medicaid PA approval adds 7 to 14 business days in most cases, making the total timeline 14 to 28 days for OHP-covered patients. Commercial PA decisions sometimes arrive faster, within 3 to 5 business days, particularly when a peer-to-peer call between the prescriber and the insurer's medical director is requested promptly. Patients awaiting PA approval can sometimes receive a short-supply manufacturer sample or pay out of pocket initially and seek reimbursement after approval.

Transferring an Existing Addyi Prescription to Oregon

Patients relocating to Oregon with an existing flibanserin prescription from another state can transfer the Rx to an Oregon-licensed pharmacy if the original prescription has refills remaining and the originating state permits transfer. Oregon pharmacy law (OAR 855-041-1060) allows transfer of non-controlled prescriptions between licensed pharmacies, including across state lines, with mutual agreement of both pharmacists [14].

A simpler path for most patients is to schedule a telehealth visit with an Oregon-licensed provider who can issue a new Oregon prescription after a brief follow-up visit. Most telehealth platforms licensed in Oregon can complete this in a single appointment. The new prescriber will want to confirm the diagnosis, current response to flibanserin, any side effects experienced (dizziness and somnolence are the most commonly reported, affecting 11 percent and 10 percent of subjects respectively in pooled Phase 3 data) [6], and ongoing alcohol abstinence.

What to Expect Clinically in the First 8 Weeks

Flibanserin is not a fast-acting drug. The FDA label specifies that patients should be evaluated at 8 weeks to determine if flibanserin is providing sufficient benefit [1]. Many Oregon clinicians schedule a follow-up video visit at 4 to 6 weeks to assess tolerability and at 8 weeks to make the efficacy decision.

In pooled Phase 3 data (N approximately 2,400 across BEGONIA, SNOWDROP, and a third North American trial), mean baseline SSEs were approximately 2.7 per month [6]. After 24 weeks of flibanserin 100 mg nightly, SSEs increased to approximately 4.5 per month versus approximately 3.7 per month with placebo. The Female Sexual Distress Scale total score dropped by a mean of 18 to 22 points from baseline in active-treatment groups [4, 5].

Somnolence is the most common early adverse effect, occurring in 10 percent of subjects in Phase 3 trials and largely mitigated by bedtime dosing [6]. Dizziness occurred in 11 percent [6]. These rates were measured at the 24-week mark; in clinical practice, many patients report accommodation within 2 to 4 weeks of consistent bedtime dosing.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction notes that "patient expectations should be calibrated to modest but meaningful improvements in desire and satisfying sexual events rather than a dramatic pharmacological response" [10]. Setting that expectation at the initial telehealth visit improves 8-week retention rates in practice.

Alcohol Interaction: The Safety Rule Oregon Patients Must Know

No other safety consideration for flibanserin is as clinically significant as the alcohol interaction. The Addyi REMS was established specifically because of hypotension and syncope risk when alcohol and flibanserin are combined. The FDA's requirement that prescribers counsel patients on alcohol abstinence is codified in the REMS program materials [1, 9].

The pharmacodynamic interaction study enrolled 25 healthy subjects and tested flibanserin with 0.4 g/kg alcohol (approximately two standard drinks for a 140 lb woman) and 0.8 g/kg alcohol. Hypotension occurred in 17 of 25 subjects (68 percent) at the higher alcohol dose and in a meaningful proportion at the lower dose. Syncope occurred in two subjects [9]. These were healthy volunteers; patients with baseline blood pressure variability face higher risk.

Oregon telehealth platforms prescribing flibanserin are required to complete REMS certification and document patient counseling. The REMS requires both the prescriber and the pharmacy to be certified through the Addyi REMS program before dispensing [1].

Finding an Oregon Telehealth Provider for Addyi

Several national telehealth platforms serving Oregon carry providers with flibanserin prescribing experience. Patients should confirm the following before booking:

1. The platform's providers hold an active Oregon license.
2. The platform pharmacy partner or preferred pharmacy is licensed in Oregon.
3. The prescriber has completed Addyi REMS certification.
4. The platform accepts OHP or the patient's commercial insurer, or offers transparent cash pricing.

Oregon's Health Authority also maintains a provider directory at oregonhealthauthority.gov that lists licensed women's health providers accepting new patients, including telehealth providers [11]. HealthRX connects Oregon patients with REMS-certified prescribers for same-week appointments and routes prescriptions to REMS-certified pharmacy partners.